Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides

被引:17
作者
Saczewski, Franciszek
Innocenti, Alessio
Brzozowski, Zdzislaw
Slawinski, Jaroslaw
Pomarnacka, Elzbieta
Kornicka, Anita
Scozzafava, Andrea
Supuran, Claudiu T. [1 ]
机构
[1] Med Univ Gdansk, Dept Chem Technol Drugs, PL-80416 Gdansk, Poland
[2] Univ Florence, Lab Chim Bioinorgan, I-50019 Florence, Italy
关键词
carbonic anhydrase; isozymes; inhibition; CA I; CA II; CA IX;
D O I
10.1080/14756360600648146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of 2-mercapto-substituted-benzenesulfonamides has been prepared by a unique two-step procedure starting from the corresponding 2-chloro-substituted benzenesulfonamides. Compounds bearing an unsubstituted mercapto group and the corresponding S-benzoyl derivatives were investigated as inhibitors of four isoforms of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), i.e., the cytosolic, ubiquitous isozymes CA I and II, as well as the transmembrane, tumor associated isozymes CA IX and XII. These derivatives were medium potency hCA I inhibitors (K(I)s in the range of 1.5 - 5.7 mu M), two derivatives were strong hCA II inhibitors (K(I)s in the range of 15 - 16 nM), whereas the others showed weak activity. These compounds inhibited hCA IX with inhibition constants in the range 160 - 1950nM and hCA XII with inhibition constants in the range 1.2 - 413 nM. Some of these derivatives showed a certain degree of selectivity for inhibition of the tumor-associated over the cytosolic isoforms, being thus interesting leads for the development of potentially novel applications in the management of hypoxic tumors which overexpress CA IX and XII.
引用
收藏
页码:563 / 568
页数:6
相关论文
共 39 条
[1]   Synthesis, antiviral, and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines [J].
Brzozowski, Z ;
Saczewski, F ;
Sanchez, T ;
Kuo, CL ;
Gdaniec, M ;
Neamati, N .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (13) :3663-3672
[2]  
Brzozowski Z, 1995, Acta Pol Pharm, V52, P287
[3]  
BRZOZOWSKI Z, 1984, ACTA POL PHARM, V41, P5
[4]  
BRZOZOWSKI Z, 1984, ACTA POL PHARM, V41, P133
[5]  
Brzozowski Z, 1995, Acta Pol Pharm, V52, P91
[6]  
Brzozowski Z, 1999, Acta Pol Pharm, V56, P135
[7]  
Brzozowski Z., 1998, ACTA POL PHARM, V55, P49
[8]   Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX [J].
Casey, JR ;
Morgan, PE ;
Vullo, D ;
Scozzafava, A ;
Mastrolorenzo, A ;
Supuran, CT .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (09) :2337-2347
[9]   Carbonic anhydrase inhibitors.: Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors [J].
Cecchi, A ;
Hulikova, A ;
Pastorek, J ;
Pastoreková, S ;
Scozzafava, A ;
Winum, JY ;
Montero, JL ;
Supuran, CT .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :4834-4841
[10]   Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma [J].
Chia, SK ;
Wykoff, CC ;
Watson, PH ;
Han, C ;
Leek, RD ;
Pastorek, J ;
Gatter, KC ;
Ratcliffe, P ;
Harris, AL .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3660-3668